Ionizable Lipid Nanoparticle Composition for Stable Nucleic Acid Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current lipid nanoparticle formulations for nucleic acid delivery face challenges such as susceptibility to nuclease digestion, limited intracellular access, and inadequate therapeutic indices, necessitating improved cationic lipid formulations that protect nucleic acids and enhance delivery efficiency.
Innovation Solution
Optimized lipid nanoparticle formulations comprising specific ratios and types of cationic, neutral, and polymer-conjugated lipids, along with a steroid, to enhance stability and delivery efficacy, including the use of lipids with varying pKa values and anionic lipids to improve encapsulation and in vivo activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If free nucleic acids are used for delivery, then they can access intracellular compartments, but they are susceptible to nuclease digestion in plasma
Solution Approach 1:
Lipid nanoparticles serve as intermediary carriers that protect nucleic acids from nuclease digestion in plasma while facilitating their delivery to intracellular compartments. The lipid nanoparticle formulation includes ionizable cationic lipids, neutral lipids, and sterols that form stable complexes with nucleic acids, shielding them from enzymatic degradation.
Solution Approach 2:
The patent optimizes the pKa values of cationic lipids (6.0-8.0) and their molar ratios in the nanoparticle formulation to achieve optimal protection against nuclease digestion while maintaining cellular uptake efficiency. The specific parameter optimization includes adjusting lipid composition ratios and pKa characteristics to balance stability and delivery.
2Reliability
If cationic lipid formulations are used to protect nucleic acids, then stability against nuclease digestion improves, but intracellular delivery efficiency is reduced
Solution Approach 1:
The patent optimizes the pKa values of cationic lipids to a specific range (6.0-8.0) and adjusts their molar ratios in the nanoparticle formulation to achieve optimal balance between protection and delivery. This parameter optimization ensures that the lipid nanoparticles maintain stability in circulation while efficiently releasing nucleic acids intracellularly.
Solution Approach 2:
The lipid nanoparticle formulation combines multiple lipid types (ionizable cationic lipids, neutral lipids, and sterols) in optimized ratios to create a composite material that simultaneously provides nuclease protection and facilitates intracellular delivery. The synergistic combination of different lipid components resolves the contradiction between stability and delivery efficiency.
3Reliability
If conventional lipid nanoparticle formulations are used, then nucleic acid protection is achieved, but therapeutic index is inadequate
Solution Approach 1:
The patent optimizes the pKa values of cationic lipids (6.0-8.0) and their molar ratios in the nanoparticle formulation to reduce toxicity and immunostimulatory activity while maintaining effective nucleic acid protection and delivery. The optimized parameters minimize harmful effects associated with conventional high-cationic-lipid formulations.
Solution Approach 2:
The patent uses localized PEGylation of specific lipid components to provide steric stabilization and reduce immunostimulatory activity at the nanoparticle surface, while maintaining the protective and delivery functions of the core lipid-nucleic acid complex. This localized modification reduces harmful effects without compromising protection.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The optimized formulations provide increased stability, enhanced delivery, and improved therapeutic indices, enabling effective intracellular delivery of nucleic acids for protein expression and gene regulation, with reduced immunostimulatory activity and toxicity.
Implementation Method 1
Lipid nanoparticles formed from cationic lipids with other lipid components, such as neutral lipids, cholesterol, PEG, PEGylated lipids, and oligonucleotides
Implementation Method 2
PEG, PEGylated lipids
Data Source
AI summary
Improved formulations of lipid nanoparticles are provided. Use of the lipid nanoparticles for delivery of a therapeutic agent and methods for their preparation are also provided.